Stocks closed modestly mixed on light volume Friday in the last full trading week of the year, which marked the third week in a row of overall gains. While drugmakers Pfizer and Merck put a damper on the Dow, robust earnings fr…
The FDA disappointed AstraZeneca and its investors by not approving its heart drug Brilinta, a blood-thinner that the company — facing a severe patent cliff — has high hopes for. If approved, it could be a multibillion-dollar…
Companies have record amounts of cash to spend: $1.9 trillion. How can they put it to the best use to keep stock markets booming?
Continue reading How Companies Should Spend Their $1.9 Trillion in Cash
…
According to the latest leaked U.S. diplomatic cables from WikiLeaks, Pfizer hired investigators to try to uncover evidence of corruption in order to pressure the Nigerian attorney general to drop the case against it.
…
Standard & Poor’s will make changes to several U.S. indexes next week, including the S&P MidCap 400, the S&P SmallCap 600, and the widely used S&P 500. The changes, which reflect the effects of acquisitions and market cap chang…